

Resource Summary Report

Generated by [NIF](#) on Sep 17, 2026

143B

RRID:CVCL_2270

Type: Cell Line

Proper Citation

RRID:CVCL_2270

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2270

Proper Citation: RRID:CVCL_2270

Description: Cell line 143B is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Osteosarcoma

Defining Citation: [PMID:2233717](#), [PMID:19787792](#), [PMID:21519327](#), [PMID:22460905](#), [PMID:23144859](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26320182](#), [PMID:26589293](#), [PMID:26852163](#), [PMID:29334376](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:36480329](#)

Comments: Caution: Could be identical to HTK- (Cellosaurus=CVCL_2522)., Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 143B

Synonyms: 143b, 143 B, 143B TK-, 143B.TK-, 143BTK-, 143TK-, HOS-143B, HOS-143b, GM05887, GM05887A

Cross References: BTO:BTO_0003167, CLO:CLO_0001084, CLO:CLO_0001088, CLO:CLO_0024221, EFO:EFO_0006355, CLDB:cl10, CLDB:cl11, ArrayExpress:E-MTAB-2706, ATCC:CRL-8303, BCRC:60439, BioGRID_ORCS_Cell_line:315, BioSample:SAMN03471904, cancercellines:CVCL_2270, CCRID:1101HUM-PUMC000363, CCRID:4201HUM-CCTCC00076, CCTCC:GDC0076, Cell_Model_Passport:SIDM00804, ChEMBL-Cells:ChEMBL3307382, ChEMBL-

Targets:CHEMBL614508, CLS:305232, Coriell:GM05887, Cosmic:1074398, Cosmic:1529910, Cosmic:2009541, DepMap:ACH-001001, ECACC:91112502, EGA:EGAS00001000610, GEO:GSM320829, GEO:GSM879206, GEO:GSM886836, GEO:GSM887899, GEO:GSM1914980, GEO:GSM1914981, GEO:GSM1914982, GEO:GSM1914983, GEO:GSM1915018, GEO:GSM1915019, GEO:GSM1915020, GEO:GSM1915021, GEO:GSM1915022, GEO:GSM2635309, GEO:GSM2635310, IARC_TP53:21149, IARC_TP53:27023, IZSLER:BS TCL 77, LINCS_LDP:LCL-1417, Lonza:136, PharmacDB:143B_3_2019, PRIDE:PXD002425, Progenetix:CVCL_2270, PubChem_Cell_line:CVCL_2270, TOKU-E:132, Wikidata:Q54581813

ID: CVCL_2270

Hierarchy: cvcl_0312

Record Creation Time: 20220427T215034+0000

Record Last Update: 20260913T011744+0000

Ratings and Alerts

No rating or validation information has been found for 143B.

No alerts have been found for 143B.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 492 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Kostas M, et al. (2026) Unconventional activation of the proto-oncogene FGFR1 by extracellular phosphate via H2O2-mediated kinase oxidation. Cell reports, 45(6), 117504.

Lin S, et al. (2026) Fluorinated polymeric nanoplatform relieves tumor hypoxia and enhances chemo-sonodynamic therapy. Acta biomaterialia, 214, 527.

Lin WW, et al. (2026) Design and Synthesis of N-Heteroacridone Derivatives and Their Ferroptosis-Inducing Activity Against Human Melanoma. ChemMedChem, 21(11), e202501070.

Malhotra SV, et al. (2026) YB-1 inhibition suppresses osteosarcoma growth and reverses tumor immunosuppression. Molecular cancer therapeutics.

Guo L, et al. (2026) The ITGB2-COPS3-SOX2 Axis and SOX2 Liquid-Liquid Phase Separation: Dual Mechanisms Governing Osteosarcoma Stemness. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(29), e20913.

- Peng M, et al. (2026) In vitro modeling of nutritional and mitochondria-targeted therapies for osteosarcoma. *bioRxiv : the preprint server for biology*.
- Duan F, et al. (2026) Inhibition of GRK2 mitigates cisplatin-induced acute and chronic nephrotoxicity by targeting the NADPH oxidase 4/oxidative stress axis. *British journal of pharmacology*, 183(12), 3149.
- Bai G, et al. (2026) LARS promotes osteosarcoma proliferation through leucine-dependent PRIM2 translation and DNA replication activation. *Journal of experimental & clinical cancer research : CR*, 45(1).
- Tao Y, et al. (2026) TENT5A Maintains MYC mRNA Stability to Enhance Osteosarcoma Stemness. *Cancer research*, 86(9), 2161.
- Yu J, et al. (2026) MnOx-armored magnesium implants for anti-osteosarcoma and biofilm eradication by charge-transfer interference. *Materials today. Bio*, 37, 102817.
- Xu G, et al. (2026) Machine Learning-Based Identification and Validation of PYCR1 and PYGM as Prognostic Biomarkers for Osteosarcoma. *Clinical Medicine Insights. Oncology*, 20, 11795549261452567.
- Wang J, et al. (2026) Prognostic characteristics of disulfidptosis-related genes across cancers and their potential implications in osteosarcoma. *Science progress*, 109(2), 368504261464856.
- N??rregaard KS, et al. (2026) The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells. *Molecular cancer therapeutics*, 25(1), 140.
- Li H, et al. (2026) Tumor Extracellular Vesicles IncOSLMT Drives Lung Inflammatory Premetastatic Niche Formation in Osteosarcoma via m6A-Dependent hnRNPA2B1/COX-2 Axis. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 13(17), e19490.
- Zhao T, et al. (2025) Derepressing nuclear pyruvate dehydrogenase induces therapeutic cancer cell reprogramming. *Cell metabolism*, 37(8), 1667.
- Wu X, et al. (2025) Development of a neutralization assay and bioluminescent imaging mouse model for Dehong virus (DEHV) using a pseudovirus system. *Microbiology spectrum*, 13(5), e0155724.
- Valeros J, et al. (2025) Rhodoquinone carries electrons in the mammalian electron transport chain. *Cell*, 188(4), 1084.
- Dai C, et al. (2025) Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. *Journal of translational medicine*, 23(1), 900.
- Zhang W, et al. (2025) Polyethylene microplastics trigger osteosarcoma progression via ITGA5/FAP??/LGMN cancer promoting complex: A novel environmental cancer promoting mechanism. *Ecotoxicology and environmental safety*, 305, 119207.
- Cheng L, et al. (2025) PEBP1 amplifies mitochondrial dysfunction-induced integrated stress response. *eLife*, 13.